Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.

Poire, Xavier;Labopin, Myriam;Polge, Emmanuelle;Ganser, Arnold;Mohty, Mohamad;et.al.
(2024) Bone Marrow Transplantation — Vol. 59, n° 2, p. 264-269 (2024)

Files

2024_Poire_Bone_Marrow_Transplant.pdf
  • Open Access
  • Adobe PDF
  • 365.7 KB
  • https://creativecommons.org/licenses/by/4.0/

Details

Authors
  • Poire, Xavierorcid-logoUCLouvain
    Author
  • Labopin, Myriamorcid-logo
    Author
  • Polge, Emmanuelle
    Author
  • Ganser, Arnold
    Author
  • Mohty, Mohamadorcid-logo
    Author
Show more
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.
Affiliations

Citations

Poire, X., Labopin, M., Polge, E., Ganser, A., Socié, G., Gedde-Dahl, T., Forcade, E., Finke, J., Chalandon, Y., Bulabois, C.-E., Yakoub-Agha, I., Aljurf, M., Kröger, N., Blau, I. W., Nagler, A., Esteve, J., & Mohty, M. (2024). Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. Bone Marrow Transplantation, 59(2), 264-269. https://doi.org/10.1038/s41409-023-02167-1 (Original work published 2024)